{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T16:20:51Z","timestamp":1784996451786,"version":"3.55.0"},"reference-count":35,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2017,9,28]],"date-time":"2017-09-28T00:00:00Z","timestamp":1506556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Paricalcitol is approved for prevention and therapy of secondary hyperparathyroidism (sHPT) in patients with chronic kidney disease (CKD), with only short-term data in clinical routine settings. A 12-month observational study was conducted in Germany and Austria (90 centers, 761 patients) from 2008 to 2013. Laboratory values, demographical, and clinical data were documented in 629 dialysis patients and 119 predialysis patients. In predialysis patients, median intact parathormone (iPTH) was 180.0 pg\/mL (n = 105) at the start of the study, 115.7 pg\/mL (n = 105) at last documentation, and 151.8 pg\/mL (n = 50) at month 12, with 32.4% of the last documented iPTH values in the KDOQI (Kidney Disease Outcomes Quality Initiative) target range. In dialysis patients, median iPTH was 425.5 pg\/mL (n = 569) at study start, 262.3 pg\/mL (n = 569) at last documentation, and 266.1 pg\/mL (n = 318) at month 12, with 36.5% of dialysis patients in the KDOQI target range. Intravenous paricalcitol showed more homogenous iPTH control than oral treatment. Combined analysis of all dialysis patients indicated comparable and stable mean serum calcium and phosphate levels throughout the study. Clinical symptoms, such as itching, bone pain, and fatigue, were improved compared with study entry. The spectrum and frequency of adverse events mirrored the known pattern for patients on dialysis. Paricalcitol is efficacious and has a consistent safety profile in sHPT over 12 months.<\/jats:p>","DOI":"10.3390\/ijms18102057","type":"journal-article","created":{"date-parts":[[2017,9,26]],"date-time":"2017-09-26T16:14:45Z","timestamp":1506442485000},"page":"2057","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-Term Therapy Outcomes When Treating Chronic Kidney Disease Patients with Paricalcitol in German and Austrian Clinical Practice (TOP Study)"],"prefix":"10.3390","volume":"18","author":[{"given":"Nicholas","family":"Oberm\u00fcller","sequence":"first","affiliation":[{"name":"Division of Nephrology, III, Medical Clinic, University Hospital Frankfurt, Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Rosenkranz","sequence":"additional","affiliation":[{"name":"Clinical Division of Nephrology, Department of Internal Medicine, Medical University Graz, Auenbruggerplatz 27, A-8036 Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Walter","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"AbbVie Deutschland GmbH &amp; Co. KG, Mainzer Strasse 81, 65189 Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Hidde","sequence":"additional","affiliation":[{"name":"AbbVie Deutschland GmbH &amp; Co. KG, Mainzer Strasse 81, 65189 Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Veres","sequence":"additional","affiliation":[{"name":"AbbVie Deutschland GmbH &amp; Co. KG, Mainzer Strasse 81, 65189 Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Decker-Burgard","sequence":"additional","affiliation":[{"name":"AbbVie Deutschland GmbH &amp; Co. KG, Mainzer Strasse 81, 65189 Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isolde","family":"Weisz","sequence":"additional","affiliation":[{"name":"AbbVie GmbH, Lemb\u00f6ckgasse 61, A-1230 Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Geiger","sequence":"additional","affiliation":[{"name":"Division of Nephrology, III, Medical Clinic, University Hospital Frankfurt, Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1152\/physrev.00014.2015","article-title":"Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects","volume":"96","author":"Christakos","year":"2016","journal-title":"Physiol. Rev."},{"key":"ref_4","first-page":"53","article-title":"Pleiotropic Activities of Vitamin D Receptors\u2014Adequate Activation for Multiple Health Outcomes","volume":"36","author":"Ryan","year":"2015","journal-title":"Clin. Biochem. Rev."},{"key":"ref_5","unstructured":"Kidney Disease: Improving Global Outcomes, CKD-MBD Work Group (2009). KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl., S1\u2013S130."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2165\/00003495-200767140-00002","article-title":"Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: Understanding the differences among therapies","volume":"67","author":"Brancaccio","year":"2007","journal-title":"Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1067\/mlc.2002.122819","article-title":"Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport","volume":"139","author":"Brown","year":"2002","journal-title":"J. Lab. Clin. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000266204","article-title":"Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients","volume":"31","author":"Lund","year":"2010","journal-title":"Am. J. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.2165\/00003495-200767140-00003","article-title":"Nonclassical aspects of differential vitamin D receptor activation: Implications for survival in patients with chronic kidney disease","volume":"67","author":"Andress","year":"2007","journal-title":"Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.semnephrol.2003.08.018","article-title":"Vitamin D receptor and analogs","volume":"24","author":"Dusso","year":"2004","journal-title":"Semin. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.atherosclerosis.2005.06.046","article-title":"Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells","volume":"186","author":"Nakane","year":"2006","journal-title":"Atherosclerosis"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jsbmb.2014.12.002","article-title":"Different vitamin D receptor agonists exhibit differential effects on endothelial function and aortic gene expression in 5\/6 nephrectomized rats","volume":"148","author":"Li","year":"2015","journal-title":"J. Steroid. Biochem. Mol. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000441364","article-title":"Paricalcitol, Microvascular and Endothelial Function in Non-Diabetic Chronic Kidney Disease: A Randomized Trial","volume":"42","author":"Lundwall","year":"2015","journal-title":"Am. J. Nephrol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis","volume":"9","author":"Martin","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000109398","article-title":"Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis","volume":"28","author":"Ross","year":"2008","journal-title":"Am. J. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","article-title":"Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD","volume":"47","author":"Coyne","year":"2006","journal-title":"Am. J. Kidney Dis."},{"key":"ref_17","first-page":"315","article-title":"A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease","volume":"56","author":"Lindberg","year":"2001","journal-title":"Clin. Nephrol."},{"key":"ref_18","first-page":"18","article-title":"The value of observational cohort studies for cancer drugs","volume":"7","author":"Spigel","year":"2010","journal-title":"Biotechnol. Healthc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0272-6386(03)00905-3","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/sj.ki.5002397","article-title":"The valuable contribution of observational studies to nephrology","volume":"72","author":"Jager","year":"2007","journal-title":"Kidney Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000357677","article-title":"Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients: A German-Austrian, single-arm, open-label, prospective, noninterventional, observational study","volume":"126","author":"Biggar","year":"2014","journal-title":"Nephron Clin. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2215\/CJN.10661013","article-title":"A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3\u20134 CKD","volume":"9","author":"Coyne","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1093\/ndt\/gfs018","article-title":"Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: Results of the IMPACT SHPT study","volume":"27","author":"Ketteler","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"320560","DOI":"10.1155\/2013\/320560","article-title":"Meta-analysis: The efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease","volume":"2013","author":"Han","year":"2013","journal-title":"BioMed Res. Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3945\/ajcn.112.040642","article-title":"High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: A pilot, randomized, double-blind, placebo-controlled trial","volume":"96","author":"Alvarez","year":"2012","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_28","first-page":"c143","article-title":"An epidemiological study of hemodialysis patients based on the European Fresenius Medical Care hemodialysis network: Results of the ARO study","volume":"118","author":"Kim","year":"2011","journal-title":"Nephron Clin. Pract."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/ndt\/gfs108","article-title":"VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH <\/= 150 pg\/mL: Results of the Italian FARO Survey","volume":"27","author":"Cozzolino","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1053\/ajkd.1998.v32.pm9808143","article-title":"Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2","volume":"32","author":"Llach","year":"1998","journal-title":"Am. J. Kidney Dis."},{"key":"ref_31","first-page":"457","article-title":"Surveillance for infections and other adverse events in dialysis patients in southern Gran Canaria","volume":"31","author":"Quori","year":"2011","journal-title":"Nefrologia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1681\/ASN.2005101078","article-title":"Revisiting survival differences by race and ethnicity among hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study","volume":"17","author":"Robinson","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S0272-6386(04)01100-X","article-title":"Mortality among hemodialysis patients in Europe, Japan, and the United States: Case-mix effects","volume":"44","author":"Goodkin","year":"2004","journal-title":"Am. J. Kidney Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ndt\/gfg483","article-title":"Mortality and hospitalization in haemodialysis patients in five European countries: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"19","author":"Rayner","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_35","unstructured":"Frei, U., and Schober-Halstenberg, H.J. (2017, March 06). Nierenersatztherapie in Deutschland Bericht 2006\u20132007 QuaSi-Niere. Available online: http:\/\/www.bundesverband-niere.de\/fileadmin\/user_upload\/QuaSi-Niere-Bericht_2006-2007.pdf."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/10\/2057\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:45:55Z","timestamp":1760208355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/10\/2057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,28]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,10]]}},"alternative-id":["ijms18102057"],"URL":"https:\/\/doi.org\/10.3390\/ijms18102057","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,28]]}}}